Compare First Horizon Corporation Common Stock (FHN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: First Horizon Corporation Common Stock is the larger of the two by market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FHN | SYRE | |
|---|---|---|
Market Cap | $10.79B | $7.52B |
Volume | 8,579,466 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $26.23 | $108.92 |
52-Week Low | $19.94 | $22.18 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.10B | $6.52B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
